Dutch Validation of the Self-Evaluation of Negative Symptoms Scale (SNS)
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Measurement Instruments
2.2.1. SNS
2.2.2. PANSS
2.2.3. HoNOS
2.2.4. GAF
2.2.5. Functional Remission
2.2.6. MANSA
2.3. Statistical Analysis
3. Results
3.1. Demographics
3.2. Psychometric Properties
3.2.1. Internal Consistency
3.2.2. Confirmatory Factor Analysis
3.2.3. Convergent and Discriminant Validity
3.3. Functional Outcomes
3.4. Quality of Life
4. Discussion
4.1. Psychometric Properties
4.1.1. Internal Consistency
4.1.2. Construct Validity
4.2. Convergent and Discriminant Validity
4.3. Functioning and Quality of Life
4.4. Strengths and Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bleuler, E. Dementia Praecox or the Group of Schizophrenias; International Universities Press: New York, NY, USA, 1950. [Google Scholar]
- Kraepelin, E. Dementia Praecox and Paraphrenia; Chicago Medical Book Company: Chicago, IL, USA, 1919. [Google Scholar]
- van der Heiden, W.; Leber, A.; Häfner, H. Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2016, 266, 387–396. [Google Scholar] [CrossRef]
- Mäkinen, J.; Miettunen, J.; Isohanni, M.; Koponen, H. Negative symptoms in schizophrenia—A review. Nord. J. Psychiatry 2008, 62, 334–341. [Google Scholar] [CrossRef]
- Bobes, J.; Arango, C.; Garcia-Garcia, M.; Rejas, J. Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice. J. Clin. Psychiatry 2010, 71, 280–286. [Google Scholar] [CrossRef]
- Fervaha, G.; Foussias, G.; Agid, O.; Remington, G. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur. Psychiatry 2014, 29, 449–455. [Google Scholar] [CrossRef] [PubMed]
- Rabinowitz, J.; Levine, S.Z.; Garibaldi, G.; Bugarski-Kirola, D.; Berardo, C.G.; Kapur, S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophr. Res. 2012, 137, 147–150. [Google Scholar] [CrossRef] [PubMed]
- Correll, C.U.; Schooler, N.R. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr. Dis. Treat. 2020, 16, 519–534. [Google Scholar] [CrossRef]
- van der Heiden, W.; Häfner, H. The epidemiology of onset and course of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2000, 250, 292–303. [Google Scholar] [CrossRef] [PubMed]
- Devoe, D.J.; Braun, A.; Seredynski, T.; Addington, J. Negative Symptoms and Functioning in Youth at Risk of Psychosis: A Systematic Review and Meta-analysis. Harv. Rev. Psychiatry 2020, 28, 341–355. [Google Scholar] [CrossRef] [PubMed]
- Salazar de Pablo, G.; Catalan, A.; Vaquerizo Serrano, J.; Pedruzo, B.; Alameda, L.; Sandroni, V.; Armendariz, A.; Rodriguez, V.; Arango, C.; Moreno, C.; et al. Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: Systematic review and meta-analysis. Br. J. Psychiatry 2023, 223, 282–294. [Google Scholar] [CrossRef]
- Aleman, A.; Lincoln, T.M.; Bruggeman, R.; Melle, I.; Arends, J.; Arango, C.; Knegtering, H. Treatment of negative symptoms: Where do we stand, and where do we go? Schizophr. Res. 2017, 186, 55–62. [Google Scholar] [CrossRef] [PubMed]
- Galderisi, S.; Kaiser, S.; Bitter, I.; Nordentoft, M.; Mucci, A.; Sabé, M.; Giordano, G.M.; Nielsen, M.; Glenthøj, L.B.; Pezzella, P.; et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur. Psychiatry 2021, 64, e21. [Google Scholar] [CrossRef] [PubMed]
- Kirkpatrick, B.; Fenton, W.S.; Carpenter, W.T.; Marder, S.R. The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophr. Bull. 2006, 32, 214–219. [Google Scholar] [CrossRef] [PubMed]
- Kay, S.R.; Fiszbein, A.; Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr. Bull. 1987, 13, 261–276. [Google Scholar] [CrossRef]
- Andreasen, N.C. Scale for the Assessment of Negative Symptoms (SANS). Br. J. Psychiatry 1989, 155, 53–58. [Google Scholar] [CrossRef]
- Kirkpatrick, B.; Strauss, G.P.; Nguyen, L.; Fischer, B.A.; Daniel, D.G.; Cienfuegos, A.; Marder, S.R. The Brief Negative Symptom Scale: Psychometric Properties. Schizophr. Bull. 2011, 37, 300–305. [Google Scholar] [CrossRef]
- Kring, A.M.; Gur, R.E.; Blanchard, J.J.; Horan, W.P.; Reise, S.P. The Clinical Assessment Interview for Negative Symptoms (CAINS): Final Development and Validation. Am. J. Psychiatry 2013, 170, 165–172. [Google Scholar] [CrossRef] [PubMed]
- Khan, A.; Yavorsky, W.C.; Liechti, S.; DiClemente, G.; Rothman, B.; Opler, M.; DeFries, A.; Jovic, S. Assessing the Sources of Unreliability (Rater, Subject, Time-Point) in a Failed Clinical Trial Using Items of the Positive and Negative Syndrome Scale (PANSS). J. Clin. Psychopharmacol. 2013, 33, 109–117. [Google Scholar] [CrossRef]
- Andreasen, N.C. Negative Symptoms in Schizophrenia Definition and Reliability. Arch. Gen. Psychiatry 1982, 39, 784–788. [Google Scholar] [CrossRef]
- David, A.S. Insight and psychosis. Br. J. Psychiatry 1990, 156, 798–808. [Google Scholar] [CrossRef] [PubMed]
- Tandon, R.; Nasrallah, H.A.; Keshavan, M.S. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110, 1–23. [Google Scholar] [CrossRef]
- Myin-Germeys, I.; Delespaul, P.A.E.G.; deVries, M.W. Schizophrenia Patients Are More Emotionally Active Than Is Assumed Based on Their Behavior. Schizophr. Bull. 2000, 26, 847–854. [Google Scholar] [CrossRef] [PubMed]
- Kring, A.M.; Kerr, S.L.; Smith, D.A.; Neale, J.M. Flat affect in schizophrenia does not reflect diminished subjective experience of emotion. J. Abnorm. Psychol. 1993, 102, 507–517. [Google Scholar] [CrossRef]
- Berenbaum, H.; Oltmanns, T.F. Emotional experience and expression in schizophrenia and depression. J. Abnorm. Psychol. 1992, 101, 37–44. [Google Scholar] [CrossRef]
- Song, J.; Borlido, C.; De Luca, V.; Burton, L.; Remington, G. Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. Psychiatry Res. 2019, 274, 409–413. [Google Scholar] [CrossRef]
- Dollfus, S.; Mach, C.; Morello, R. Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms. Schizophr. Bull. 2016, 42, 571–578. [Google Scholar] [CrossRef]
- Wójciak, P.; Górna, K.; Domowicz, K.; Jaracz, K.; Szpalik, R.; Michalak, M.; Rybakowski, J. Polish version of the Self-evaluation of Negative Symptoms (SNS). Psychiatr. Pol. 2019, 53, 551–559. [Google Scholar] [CrossRef]
- Rodríguez-Testal, J.F.; Perona-Garcelán, S.; Dollfus, S.; Valdés-Díaz, M.; García-Martínez, J.; Ruíz-Veguilla, M.; Senín-Calderón, C. Spanish validation of the self-evaluation of negative symptoms scale SNS in an adolescent population. BMC Psychiatry 2019, 19, 327. [Google Scholar] [CrossRef]
- Hajj, A.; Hallit, S.; Chamoun, K.; Sacre, H.; Obeid, S.; Haddad, C.; Dollfus, S.; Khabbaz, L.R. Validation of the Arabic version of the “self-evaluation of negative symptoms” scale (SNS). BMC Psychiatry 2020, 20, 240. [Google Scholar] [CrossRef]
- Montvidas, J.; Adomaitienė, V.; Leskauskas, D.; Dollfus, S. Validation of the lithuanian version of the self-evaluation of negative symptoms scale (SNS). Nord. J. Psychiatry 2021, 75, 351–355. [Google Scholar] [CrossRef]
- Tam, M.H.; Ling-Ling, W.; Cheng, K.M.; Wong, J.O.; Cheung, E.F.; Lui, S.S.; Chan, R.C. Latent structure of self-report negative symptoms in patients with schizophrenia: A preliminary study. Asian J. Psychiatr. 2021, 61, 102680. [Google Scholar] [CrossRef]
- Mazhari, S.; Karamooz, A.; Shahrbabaki, M.E.; Jahanbakhsh, F.; Dollfus, S. Validity and reliability of a Persian version of the self- evaluation of negative symptoms (SNS). BMC Psychiatry 2021, 21, 516. [Google Scholar] [CrossRef]
- Polat, I.; Ince Guliyev, E.; Elmas, S.; Karakaş, S.; Aydemir, Ö.; Üçok, A. Validation of the Turkish version of the self-evaluation of negative symptoms scale (SNS). Int. J. Psychiatry Clin. Pract. 2022, 26, 221–227. [Google Scholar] [CrossRef]
- Dollfus, S.; Mucci, A.; Giordano, G.M.; Bitter, I.; Austin, S.F.; Delouche, C.; Erfurth, A.; Fleischhacker, W.W.; Movina, L.; Glenthøj, B.; et al. European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. Front. Psychiatry. 2022, 13, 826465. [Google Scholar] [CrossRef]
- Mallet, J.; Guessoum, S.B.; Tebeka, S.; Le Strat, Y.; Dubertret, C. Self-evaluation of negative symptoms in adolescent and young adult first psychiatric episodes. Prog. Neuropsychopharmacol. Biol. Psychiatry 2020, 103, 109988. [Google Scholar] [CrossRef] [PubMed]
- Bartels-Velthuis, A.A.; Visser, E.; Arends, J.; Pijnenborg, G.H.; Wunderink, L.; Jörg, F.; Veling, W.; Liemburg, E.J.; Castelein, S.; Knegtering, H.; et al. Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS). Schizophr. Res. 2018, 197, 281–287. [Google Scholar] [CrossRef] [PubMed]
- Prinsen, C.A.C.; Mokkink, L.B.; Bouter, L.M.; Alonso, J.; Patrick, D.L.; de Vet, H.C.W.; Terwee, C.B. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual. Life Res. 2018, 27, 1147–1157. [Google Scholar] [CrossRef] [PubMed]
- Wing, J.K.; Beevor, A.S.; Curtis, R.H.; Park, S.G.B.; Hadden, J.; Burns, A. Health of the Nation Outcome Scales (HoNOS). Br. J. Psychiatry 1998, 172, 11–18. [Google Scholar] [CrossRef] [PubMed]
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; American Psychiatric Association: Washington, DC, USA, 2000. [Google Scholar]
- Wiersma, D.; Visser, E.; Bähler, M.; Bruggeman, R.; A Delespaul, P.; Van Der Gaag, M.; De Haan, L.; Keet, I.P.M.; Nijssen, Y.; Van Os, J.; et al. [Functional remission of people with serious mental illness (SMI): Psychometric properties of a new ROM-instrument]. Tijdschr. Psychiatr. 2015, 57, 395–404. [Google Scholar]
- Taber, K.S. The Use of Cronbach’s Alpha When Developing and Reporting Research Instruments in Science Education. Res. Sci. Educ. 2018, 48, 1273–1296. [Google Scholar] [CrossRef]
- Brown, T.A. Confirmatory Factor Analysis for Applied Research; The Guilford Press: New York, NY, USA, 2006. [Google Scholar]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2023. [Google Scholar]
- Revelle, W. psych: Procedures for Psychological, Psychometric, and Personality Research. Available online: https://CRAN.R-project.org/package=psych (accessed on 1 January 2023).
- Rosseel, Y. lavaan: An R Package for Structural Equation Modeling. J. Stat. Softw. 2012, 48, 1–36. [Google Scholar] [CrossRef]
- Tierney, N.; Cook, D. Expanding Tidy Data Principles to Facilitate Missing Data Exploration, Visualization and Assessment of Imputations. J. Stat. Softw. 2023, 105, 1–31. [Google Scholar] [CrossRef]
- Bora, E.; Pantelis, C. Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: Systematic review and meta-analysis. Schizophr. Res. 2013, 144, 31–36. [Google Scholar] [CrossRef]
- van Neerven, T.; Bos, D.J.; van Haren, N.E. Deficiencies in Theory of Mind in patients with schizophrenia, bipolar disorder, and major depressive disorder: A systematic review of secondary literature. Neurosci. Biobehav. Rev. 2021, 120, 249–261. [Google Scholar] [CrossRef] [PubMed]
- Horan, W.P.; Kring, A.M.; Blanchard, J.J. Anhedonia in Schizophrenia: A Review of Assessment Strategies. Schizophr. Bull. 2006, 32, 259–273. [Google Scholar] [CrossRef] [PubMed]
- Galderisi, S.; Mucci, A.; Buchanan, R.W.; Arango, C. Negative symptoms of schizophrenia: New developments and unanswered research questions. Lancet Psychiatry 2018, 5, 664–677. [Google Scholar] [CrossRef] [PubMed]
- Kiang, M.; Christensen, B.K.; Remington, G.; Kapur, S. Apathy in schizophrenia: Clinical correlates and association with functional outcome. Schizophr. Res. 2003, 63, 79–88. [Google Scholar] [CrossRef]
- Konstantakopoulos, G.; Ploumpidis, D.; Oulis, P.; Patrikelis, P.; Soumani, A.; Papadimitriou, G.N.; Politis, A.M. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr. Res. 2011, 133, 193–198. [Google Scholar] [CrossRef] [PubMed]
- Strauss, G.P.; Horan, W.P.; Kirkpatrick, B.; Fischer, B.A.; Keller, W.R.; Miski, P.; Buchanan, R.W.; Green, M.F.; Carpenter, W.T. Deconstructing negative symptoms of schizophrenia: Avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J. Psychiatr. Res. 2013, 47, 783–790. [Google Scholar] [CrossRef]
- Mucci, A.; Vignapiano, A.; Bitter, I.; Austin, S.F.; Delouche, C.; Dollfus, S.; Erfurth, A.; Fleischhacker, W.W.; Giordano, G.M.; Gladyshev, I.; et al. A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. Eur. Neuropsychopharmacol. 2019, 29, 947–959. [Google Scholar] [CrossRef]
- Okada, H.; Hirano, D.; Taniguchi, T. Impact of Negative Symptom Domains and Other Clinical Characteristics on Functional Outcomes in Patients with Schizophrenia. Schizophr. Res. Treatment. 2021, 2021, 8864352. [Google Scholar] [CrossRef] [PubMed]
- Messinger, J.W.; Trémeau, F.; Antonius, D.; Mendelsohn, E.; Prudent, V.; Stanford, A.D.; Malaspina, D. Avolition and expressive deficits capture negative symptom phenomenology: Implications for DSM-5 and schizophrenia research. Clin. Psychol. Rev. 2011, 31, 161–168. [Google Scholar] [CrossRef] [PubMed]
- Foussias, G.; Siddiqui, I.; Fervaha, G.; Agid, O.; Remington, G. Dissecting negative symptoms in schizophrenia: Opportunities for translation into new treatments. J. Psychopharmacol. 2015, 29, 116–126. [Google Scholar] [CrossRef] [PubMed]
- Green, M.F.; Hellemann, G.; Horan, W.P.; Lee, J.; Wynn, J.K. From perception to functional outcome in schizophrenia: Modeling the role of ability and motivation. Arch. Gen. Psychiatry 2012, 69, 1216–1224. [Google Scholar] [CrossRef]
- Fervaha, G.; Foussias, G.; Agid, O.; Remington, G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Res. 2013, 210, 665–668. [Google Scholar] [CrossRef] [PubMed]
- Galderisi, S.; Rossi, A.; Rocca, P.; Gibertoni, D.; Aguglia, E.; Amore, M.; Bellomo, A.; Biondi, M.; Brugnoli, R.; Dell, L.; et al. The Influence of Illness-Related Variables, Personal Resources and Context-Related Factors on Real-Life Functioning of People with Schizophrenia. World Psychiatry 2014, 13, 275–287. [Google Scholar] [CrossRef] [PubMed]
- Rocca, P.; Montemagni, C.; Zappia, S.; Piterà, R.; Sigaudo, M.; Bogetto, F. Negative symptoms and everyday functioning in schizophrenia: A cross-sectional study in a real world-setting. Psychiatry Res. 2014, 218, 284–289. [Google Scholar] [CrossRef] [PubMed]
- Ventura, J.; Subotnik, K.L.; Gitlin, M.J.; Gretchen-Doorly, D.; Ered, A.; Villa, K.F.; Hellemann, G.S.; Nuechterlein, K.H. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8years later. Schizophr. Res. 2015, 161, 407–413. [Google Scholar] [CrossRef] [PubMed]
- Montvidas, J.; Adomaitienė, V.; Leskauskas, D.; Dollfus, S. Correlation of Health-Related Quality of Life with Negative Symptoms Assessed with the Self-Evaluation of Negative Symptoms Scale (SNS) and Cognitive Deficits in Schizophrenia: A Cross-Sectional Study in Routine Psychiatric Care. J. Clin. Med. 2023, 12, 901. [Google Scholar] [CrossRef] [PubMed]
Mean (SD) | % (N) | |
---|---|---|
Age | 42.9 (12.5) | |
Gender (Female) | 34.4 (85) | |
Diagnosis | ||
Schizophrenia | 37.80 (93) | |
Schizoaffective disorder | 11.38 (28) | |
Bipolar disorder | 6.91 (17) | |
Other psychotic disorder | 44.31 (109) | |
Education 1 | ||
Lower | 20.65 (51) | |
Middle | 51.82 (128) | |
Higher | 26.32 (65) | |
Daily activities | ||
Job | 27.53 (68) | |
Volunteering | 21.05 (52) | |
Day care | 19.43 (48) | |
Household | 12.15 (30) | |
Study | 8.10 (20) | |
Family care | 1.21 (3) | |
None | 23.48 (58) | |
SNS total | 12.6 (7.43) | |
Social withdrawal | 2.42 (2.03) | |
Reduced emotional range | 2.79 (1.95) | |
Alogia | 2.49 (2.02) | |
Avolition | 2.83 (2.24) | |
Anhedonia | 2.11 (1.86) | |
PANSS total 2 | 40.4 (10.3) | |
Positive subscale | 9.79 (3.18) | |
Negative subscale | 9.57 (3.73) | |
General subscale | 21.0 (5.07) | |
HoNOS 3 | 6.60 (5.06) | |
GAF 4 | 57.0 (11.1) | |
FR 5 | 2.42 (1.67) | |
MANSA 6 | 59.3 (12.0) |
Cronbach’s Alpha [CI 95%] | |
---|---|
SNS total | 0.87 [0.85–0.90] |
Social withdrawal | 0.76 [0.71–0.80] |
Reduced emotional range | 0.64 [0.56–0.71] |
Alogia | 0.71 [0.65–0.77] |
Avolition | 0.79 [0.75–0.83] |
Anhedonia | 0.69 [0.62–0.75] |
SNS Subscores | Reduced Emotional Range | Alogia | Avolition | Anhedonia |
---|---|---|---|---|
Social withdrawal | 0.37 *** [0.25–0.48] | 0.48 *** [0.38–0.58] | 0.43 *** [0.31–0.54] | 0.48 *** [0.37–0.57] |
Reduced emotional range | 0.42 *** [0.31–0.53] | 0.25 *** [0.13–0.37] | 0.42 *** [0.30–0.52] | |
Alogia | 0.38 *** [0.27–0.48] | 0.51 *** [0.40–0.60] | ||
Avolition | 0.52 *** [0.41–0.61] |
PANSS Total (N = 207) | PANSS Positive | PANSS Negative | PANSS General | HoNOS (N = 187) | GAF (N = 134) | FR (N = 198) | MANSA (N = 182) | |
---|---|---|---|---|---|---|---|---|
SNS total | 0.36 *** [0.24–0.48] | 0.31 *** [0.19–0.42] | 0.33 *** [0.20–0.43] | 0.30 *** [0.16–0.42] | 0.37 *** [0.21–0.49] | −0.12 [−0.28–0.037] | 0.27 *** [0.14–0.39] | −0.40 *** [−0.52–−0.25] |
Social withdrawal | 0.29 *** [0.15–0.42] | 0.31 *** [0.18–0.43] | 0.31 *** [0.17–0.43] | 0.19 * [0.042–0.32] | 0.32 *** [0.16–0.46] | −0.19 * [−0.34–−0.028] | 0.27 *** [0.12–0.40] | −0.22 ** [−0.37–−0.075] |
Reduced emotional range | 0.19 ** [0.053–0.31] | 0.18 ** [0.042–0.31] | 0.19 ** [0.057–0.31] | 0.13 [−0.0078–0.26] | 0.18 * [0.045–0.32] | −0.046 [−0.20–0.13] | 0.097 [−0.029–0.22] | −0.12 [−0.27–0.028] |
Alogia | 0.21 ** [0.075–0.33] | 0.13 [−0.013–0.26] | 0.21 ** [0.081–0.34] | 0.20 ** [0.072–0.32] | 0.23 ** [0.060–0.37] | −0.015 [−0.18–0.15] | 0.12 [−0.0082–0.26] | −0.29 *** [−0.43–−0.16] |
Avolition | 0.34 *** [0.22–0.46] | 0.29 *** [0.17–0.42] | 0.25 *** [0.12–0.37] | 0.31 *** [0.18–0.43] | 0.35 *** [0.21–0.48] | −0.084 [−0.26–0.090] | 0.25 *** [0.12–0.37] | −0.46 *** [−0.59–−0.32] |
Anhedonia | 0.27 *** [0.13–0.40] | 0.20 ** [0.066–0.32] | 0.22 ** [0.090–0.36] | 0.25 *** [0.12–0.38] | 0.23 ** [0.074–0.38] | −0.086 [−0.25–0.077] | 0.19 ** [0.045–0.32] | −0.36 *** [−0.48–−0.21] |
PANSS total | x | 0.82 *** [0.75–0.87] | 0.78 *** [0.71–0.84] | 0.92 *** [0.90–0.94] | 0.56 *** [0.44–0.65] | −0.57 *** [−0.69–−0.42] | 0.57 *** [0.46–0.66] | −0.43 *** [−0.55–−0.30] |
PANSS positive | x | 0.53 *** [0.41–0.64] | 0.65 *** [0.55–0.75] | 0.50 *** [0.37–0.61] | −0.48 *** [−0.62–−0.32] | 0.52 *** [0.40–0.63] | −0.34 *** [−0.47–−0.19] | |
PANSS negative | x | 0.61 *** [0.51–0.70] | 0.44 *** [0.30–0.56] | −0.43 *** [−0.59–−0.26] | 0.53 *** [0.42–0.63] | −0.35 *** [−0.48–−0.20] | ||
PANSS general | x | 0.50 *** [0.37–0.61] | −0.53 *** [−0.65–−0.38] | 0.49 *** [0.37–0.60] | −0.42 *** [−0.55–−0.29] |
PANSS Positive | PANSS Negative | |
---|---|---|
SNS total | 0.066 [−0.14–0.26] | 0.26 ** [0.063–0.44] |
Social withdrawal | 0.27 ** [0.090–0.44] | 0.31 ** [0.12–0.50] |
Reduced emotional range | −0.11 [−0.30–0.087] | 0.061 [−0.14–0.27] |
Alogia | −0.059 [−0.26–0.16] | 0.24 * [0.055–0.41] |
Avolition | 0.11 [−0.075–0.29] | 0.21 * [−0.0038–0.39] |
Anhedonia | −0.010 [−0.22–0.19] | 0.12 [−0.092–0.32] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
van Brouwershaven, T.; Poppe, A.; Pijnenborg, G.H.M.; Aleman, A.; Boonstra, N.; Gangadin, S.; Dollfus, S.; Veling, W.; Castelein, S.; de Vos, J.A.; et al. Dutch Validation of the Self-Evaluation of Negative Symptoms Scale (SNS). Brain Sci. 2025, 15, 15. https://doi.org/10.3390/brainsci15010015
van Brouwershaven T, Poppe A, Pijnenborg GHM, Aleman A, Boonstra N, Gangadin S, Dollfus S, Veling W, Castelein S, de Vos JA, et al. Dutch Validation of the Self-Evaluation of Negative Symptoms Scale (SNS). Brain Sciences. 2025; 15(1):15. https://doi.org/10.3390/brainsci15010015
Chicago/Turabian Stylevan Brouwershaven, Tim, Anika Poppe, Gerdina Hendrika Maria Pijnenborg, André Aleman, Nynke Boonstra, Shiral Gangadin, Sonia Dollfus, Wim Veling, Stynke Castelein, Jan Alexander de Vos, and et al. 2025. "Dutch Validation of the Self-Evaluation of Negative Symptoms Scale (SNS)" Brain Sciences 15, no. 1: 15. https://doi.org/10.3390/brainsci15010015
APA Stylevan Brouwershaven, T., Poppe, A., Pijnenborg, G. H. M., Aleman, A., Boonstra, N., Gangadin, S., Dollfus, S., Veling, W., Castelein, S., de Vos, J. A., Liemburg, E., PHAMOUS-researchers, & van der Meer, L. (2025). Dutch Validation of the Self-Evaluation of Negative Symptoms Scale (SNS). Brain Sciences, 15(1), 15. https://doi.org/10.3390/brainsci15010015